SEC Filing Summary: RXi Pharmaceuticals Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by RXi Pharmaceuticals Corporation (now known as SELLAS Life Sciences Group, Inc.) on April 18, 2011. The report addresses a regulatory matter concerning the company's continued listing on The Nasdaq Stock Market.
Key Financial Metrics
- Stockholders' Equity: The filing references a pro forma balance sheet showing stockholders' equity of $7,370,000 as of March 31, 2011.
- Listing Requirement: Nasdaq Listing Rule 5550(b)(1) requires a minimum of $2,500,000 in stockholders' equity.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity beyond the equity figure.
Material Changes and Events
On April 18, 2011, the company received a notice from Nasdaq stating it failed to comply with Listing Rule 5550(b)(1) based on its Form 10-K, as it appeared to have less than the required $2,500,000 in stockholders' equity. The company also did not meet alternative listing standards regarding market value of listed securities or net income from continuing operations as of April 15, 2011.
Subsequently, on April 20, 2011, the company submitted a pro forma balance sheet demonstrating that equity had been $7,370,000 as of March 31, 2011, and had remained above the $2,500,000 threshold since that date.
Outlook, Risks, and Resolution
Nasdaq confirmed on April 21, 2011, that the company is in compliance with Listing Rule 5550(b)(1) and closed the matter. The risk of delisting due to insufficient stockholders' equity was resolved following the submission of the pro forma financial data.
Key Facts for Investor Verification
- Verify the accuracy of the pro forma balance sheet submitted to Nasdaq showing $7,370,000 in equity as of March 31, 2011.
- Confirm the company's current compliance status with Nasdaq listing standards beyond the equity requirement.
- Review the underlying Form 10-K that initially triggered the delisting notice to understand the discrepancy in reported equity.